Direct Oral Anticoagulant Use: A Practical Guide to Common
irect oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the preven- tion of thrombosis in several cardiovascular contexts.1
Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts. 1 DOACs are categorized into 2 main classes: oral direct factor Xa inhibitors (ie,
Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts.1 DOACs are categorized into 2 main classes: oral direct factor Xa inhibitors (ie, rivaroxaban, apixaban, edoxaban, and betrixaban) and
Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions.
Direct Oral Anticoagulants: A Quick Guide - Expert Review - ISCP
In recent years, four direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban and edoxaban, have been compared with warfarin for stroke prevention in AF, in large, phase 3, randomised, controlled trials (RCTs). Various terms have been used to describe these drugs, including new/ novel oral anticoagulants or non-vitamin K oral
- What are direct oral anticoagulants?
- Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for prevention and treatment of several cardiovascular conditions.
- Are direct oral anticoagulants used for thromboembolic indications?
- Direct oral anticoagulants are used worldwide for several thromboembolic indications. The 2018 ICSH document provided haemostasis-related guidance for clinical laboratories. This study addressed all phases of laboratory DOAC measurements. What does this paper add?
- What are direct oral anticoagulants (DOACs)?
- 3 Center for Preventive Cardiology Knight Cardiovascular Institute Oregon Health & Science University Portland OR. Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist.
- Can a patient transition from anticoagulants to DOAC therapy?
- As with any high‐risk medication such as anticoagulants, clinical situations may arise that require transitioning to or off of DOAC therapy. Two common transition scenarios include (1) switching between anticoagulants and (2) periprocedural management.
- Are anticoagulant effects of DOACs useful in laboratory assessment and testing?
- Thus, potential influence of DOACs has always to be considered when interpreting abnormal functional coagulation assays. The objective of this review was to update systematically evidence regarding usefulness and pitfalls in laboratory assessment and testing of the anticoagulant effects of DOACs. 1. Introduction
- Why do clinicians need a DOAC?
- With the expanding role of DOACs, clinicians are faced with increasingly complex decisions relating to appropriate agent, duration of treatment, and use in special populations. This review will provide an overview of DOACs and act as a practical reference for clinicians to optimize DOAC use among common challenging scenarios.
